Benzinga -
- The European Commission has approved Sanofi (EPA:SASY) SA (NASDAQ: SNY) and GSK plc (NYSE: GSK) partnered COVID-19 vaccine booster after the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion.
- The shot with the brand name VidPrevtyn Beta can be given to people who have already had a primary vaccination course from other approved shots.
- It is based on lab-made viral proteins provided by Sanofi and an adjuvant ingredient from GSK that increases the immune response.
- The companies' bivalent vaccine targets the Beta variant as well as the original Wuhan strain of the virus. Trial results also showed that the shot confers protection against the Omicron variant.
- The European Medicines Agency said that study shows that a booster dose of VidPrevtyn Beta should be at least as effective as Comirnaty from Pfizer Pfizer Inc (NYSE: NYSE:PFE) and BioNTech SE (NASDAQ: BNTX).
- The first generation of their joint candidate did not produce the desired protection for the elderly in 2020.
- Price Action: SNY shares are up 1.80% at $44.12, and GSK stock is up 2.50% at $33.23 on the last check Thursday.